 |
Mount Sinai School of Medicine | |
| City: New York | State: NY | |
|
Links:
Commentary:Mt._Sinai_external_relationships.pdf Mt._Sinai_Industry_Relationships.htm Mt.Sinai_-_COI_Policy.doc Mt.Sinai_-_Industry_support_of_CME.doc Mt_Sinai_Curriculum.pdf A complete ban on gifts and strong policies on purchasing decisions and pharmaceutical samples set the policies on industry interactions at Mount Sinai School of Medicine apart. The institution's rigorous oversight of external speaking and consulting relationships is noteworthy, as each must be reviewed and approved prior to commencement. If preventive language on long-term speaking relationships were added (to clarify what may already be procedurally true through the oversight process) this policy would be even stronger. Additionally, public disclosure of financial relationships with industry would go even further to promote transparency.
Mount Sinai School of Medicine provided updated policies covering consulting relationships and curriculum for the 2009 AMSA PharmFree Scorecard. Their grade remains an A.
This institution's evaluation was last updated: 6/16/2009
|
||
| Gifts & Meals |  |
This is an exemplary policy that defines gifts, bans their receipt by faculty, staff and trainees, and removes ambiguity by providing specific examples of many types of gifts. |
| Consulting relationships | |
Consulting relationships must be described in a written contract, and there are limits as to how frequently and for how long a physician may serve as a consultant. |
| Industry-funded speaking relationships |  |
Although this policy does not prevent long-term speaking relationships, in all other areas it is exemplary. Speaking relationships must be approved by the institution, and presentation content must reflect the faculty member's own work. This policy also explicitly acknowledges the potential for speaking relationships to act as a vehicle for industry promotion. |
| Disclosure | |
This policy does not provide for public or patient disclosure of faculty financial relationships, but it does require annual filing of conflict of interest statements by those serving on committees making purchasing decisions and those with financial relationships with extramural entities. |
| Pharmaceutical samples | |
Samples are only allowed for specific exceptions that exist for patient benefit: |
| Purchasing & Formularies | |
Exemplary policy. Individuals may not take part in decisions or discussions wherein they have a financial conflict with the company in question or a competitor of that company. |
| Industry Sales Representatives | |
This policy refers to a "Medical Sales Representatives policy" that was not provided. The score is based on the Education and Training on Vendor's Own Products section of the policy, which states that Industry representatives are allowed on site with appointment. |
| On-campus Education | |
While contributions for most educational events must be made to a centralized, independent general fund, Mount Sinai SOM does allow non-centralized sponsorship of individual CME-credit-granting educational programs when they apply to offer such programs with Mount Sinai SOM and adhere to Standards for Commercial Support of the Accreditation Council for Continuing Medical Education (ACCME). |
| Attendance at Industry-Sponsored Lectures & Meetings Off-Campus | |
This policy explicitly warns of the potential bias in educational events, including speakers’ bureaus, but allows vendor support for off-site educational events as long as donations are unrestricted and made to a departmental education fund and industry may not select the recipients. |
| Industry Support for Scholarships & Funds for Trainees | |
Industry may not choose the recipient of support for educational events. |
| Medical school curriculum | |
The curriculum shows clear evidence of covering conflict of interest and pharmaceutical industry influence in a substantial way. |
| Do the policies specify an oversight mechanism? |  |
There is no general oversight mechanism. |
| Are there explicit sanctions for noncompliance? | |
There is no reference to sanctions. |
 | |
 | Model policy |
 | Good progress toward model policy |
 | No policy, or policy unlikely to have a substantial effect on behavior |
 | Did not report |
 | Policy not relevant to this institution (e.g., does not make purchasing decisions) |
